Latest

Latest AstraZeneca News | Page 5

  • Latest AstraZeneca news stories and updates. What is happening today? All recent AstraZeneca news and developments. Live coverage and timeline of AstraZeneca. All you need to know about AstraZeneca.
Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Tezspire approved in EU for treatment of severe asthma
Evusheld long-acting antibody combination approved in EU for treatment of Covid
Treatment offers new hope for lupus – and maybe for other autoimmune diseases too
Danicopan add-on to Ultomiris or Soliris met primary endpoint
Evusheld long-acting antibody combination recommended for approval in EU for treatment of Covid
Beyfortus recommended for approval in EU by CHMP for prevention of RSV lower respiratory tract disease in infants
New support for lung cancer patients
Imfinzi plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer
Imfinzi and tremelimumab with chemotherapy demonstrated sustained survival benefit
Enhertu continues to demonstrate clinically meaningful tumour response
Tagrisso demonstrated 5.5-year median disease-free survival in adjuvant treatment of patients with EGFR-mutated lung cancer
Lynparza in combination with bevacizumab, and as monotherapy, demonstrates clinically meaningful survival benefit
Forxiga approved in China for treatment of chronic kidney disease in patients
Imfinzi plus chemotherapy approved in US as first immunotherapy regimen for patients with advanced biliary tract cancer
Covid vaccine difference between men and women
Better COVID vaccines are on way
First new treatment in more than 20 years added to PBS for people living with proteinuric chronic kidney disease
Evusheld long-acting antibody combination approved for prevention and treatment of Covid in Japan
Should states cut COVID isolation from 7 to 5 days?
New data show Farxiga significantly lowers risk of cardiovascular death in patients with heart failure
Farxiga significantly reduced risk of cardiovascular death or worsening of heart failure
Ultomiris approved in Japan for treatment of adults with generalised myasthenia gravis
Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
Victorian Government funding accelerates new approaches to vaccine development for ovarian cancer
Researchers identified markers of chemotherapy resistance and outcome in triple negative breast cancer
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Auditor general highlights vaccine rollout failures
Lynparza in combination with abiraterone granted Priority Review in US for patients with metastatic castration-resistant prostate
Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial vs. physician’s choice of treatment
Enhertu approved in US as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell
Acquisition of TeneoTwo for its clinical-stage T-cell engager completed
Starpharma announces new research agreement for DEP drug delivery platform
Datopotamab deruxtecan-based combinations show promising clinical activity
Enhertu approved in US as first HER2-directed therapy for patients with HER2-low metastatic breast cancer
Calquence tablet formulation approved in US across current indications
Lynparza approved in EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Michel Demaré to succeed Leif Johansson as Non-Executive Chair of Board
H1 2022 results
Tezspire recommended for approval in EU by CHMP for treatment of severe asthma
Ultomiris recommended for approval in EU by CHMP for treatment of adults with generalised myasthenia gravis
Enhertu granted Priority Review in US for patients with HER2-low metastatic breast cancer
Enhertu approved in EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based
Nuclear medicine funding a win for men with prostate cancer
Starpharma signs expanded DEP research agreemnent with Genentech
AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK life sciences and leadership
Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy
AstraZeneca launches global R&D Postdoctoral Challenge to accelerate scientific discovery and diversity

© 2024 - The National Tribune Australia